✦ LIBER ✦

Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group

✍ Scribed by M. -C. Poon; L. M. Aledort; K. Anderle; M. Kunschak; M. Morfini; The Factor IX Study Group

Book ID: 114439993
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 494 KB
Volume: 35
Category: Article
ISSN: 0372-1248
DOI: 10.1046/j.1537-2995.1995.35495216081.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An open clinical study assessing the eff

An open clinical study assessing the efficacy and safety of Factor IX Grifols®, a high-purity Factor IX concentrate, in patients with severe haemophilia B

✍ T. LISSITCHKOV; M. MATYSIAK; K. ZAWILSKA; L. GERCHEVA; A. ANTONOV; M. MONTAÑES; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB

Pharmacokinetic study of a high-purity f

Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols®) with a 6-month follow up in previously treated patients with severe haemophilia B

✍ J. A. AZNAR; N. CABRERA; M. MATYSIAK; K. ZAWILSKA; L. GERCHEVA; A. ANTONOV; M. M 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB

Controlled prospective study of factor I

Controlled prospective study of factor IX concentrate therapy and immunodeficiency

✍ Mae B. Hultin; Raymond J. Dattwyler; Richard A. Lipton 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB

A cross-over pharmacokinetic and thrombo

A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate

✍ D. P. Thomas; K. K. Hampton; H. Dasani; C. A. Lee; P. L. F. Giangrande; C. Harma 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 602 KB

In vivo recovery and half-life time of a

In vivo recovery and half-life time of a steam-treated factor IX concentrate in hemophilia B patients

✍ K�hler, M. ;Seifried, E. ;Hellstern, P. ;Pindur, G. ;Miyashita, C. ;M�rsdorf, S. 📂 Article 📅 1988 🏛 Springer-Verlag ⚖ 520 KB

Factor IX (FIX) recovery and half-life was measured in ten hemophilia B patients under standardized conditions. Each patient received a steam-treated high-purity factor IX concentrate at a dose of 19-39 U/kg body weight. FIX activity was determined using a one-stage assay, which was calibrated again

Safety of high doses of a monoclonal ant

Safety of high doses of a monoclonal antibody-purified factor IX concentrate

✍ Dr. Indira Warrier; Carol K. Kasper; Gilbert C. White II; Amy D. Shapiro; Garret 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 210 KB 👁 2 views